Coloplast (CPSE:COLO B) - Prezzo delle azioni, notizie e analisi

COLO B Panoramica delle azioni

Coloplast A/S si occupa dello sviluppo e della vendita di prodotti e servizi per l'igiene intima in Danimarca, Stati Uniti, Regno Unito, Francia e a livello internazionale. Maggiori dettagli

COLO B analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	3/6
Prestazioni passate	3/6
Salute finanziaria	2/6
Dividendi	3/6

Premi

Negoziato a 41.1% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 12.85% all'anno

Gli utili sono cresciuti del 4.9% all'anno negli ultimi 5 anni

Analisi del rischio

Il debito non è ben coperto dal flusso di cassa operativo

Il dividendo di 2.47% non è ben coperto dagli utili o dai flussi di cassa liberi

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Key Takeaways Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term. Strategic acquisitions and growth in niche markets are projected to boost revenue and transform key business segments.

View narrative

DKK 911.19

2.3% undervalued

8.48%

Revenue growth p.a.

11 days ago

Coloplast A/S Concorrenti

Demant

CPSE:DEMANT

DKK 57.6b

Ambu

CPSE:AMBU B

DKK 31.7b

Embla Medical hf

CPSE:EMBLA

DKK 15.1b

Cooper Companies

NasdaqGS:COO

US$19.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Coloplast
Prezzi storici delle azioni
Prezzo attuale dell'azione	DKK 890.00
Massimo di 52 settimane	DKK 977.60
Minimo di 52 settimane	DKK 739.60
Beta	0.34
1Variazione di 1 mese	-0.71%
Variazione a 3 mesi	0.25%
Variazione di 1 anno	18.32%
3Variazione a 3 anni	-24.67%
Variazione a 5 anni	11.33%
Variazione dall'IPO	6,865.22%

Notizie e aggiornamenti recenti

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Recent updates

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Rendimenti per gli azionisti

	COLO B	DK Medical Equipment	DK Mercato
7D	-4.2%	-1.2%	-3.1%
1Y	18.3%	16.5%	5.7%

Ritorno vs Industria: COLO B ha superato il Danish Medical Equipment che ha restituito 16.5 % nell'ultimo anno.

Rendimento vs Mercato: COLO B ha superato il mercato Danish che ha restituito 5.7 % nell'ultimo anno.

Volatilità dei prezzi

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Average Weekly Movement	3.7%
Medical Equipment Industry Average Movement	3.7%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Prezzo delle azioni stabile: COLO B non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di COLO B è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1954	16,639	Kristian Villumsen	www.coloplast.com

Coloplast A/S si occupa dello sviluppo e della vendita di prodotti e servizi per l'igiene intima in Danimarca, Stati Uniti, Regno Unito, Francia e a livello internazionale. L'azienda opera attraverso i segmenti Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology e Advanced Wound Care. L'azienda fornisce prodotti per la cura delle stomie, tra cui SenSura Mio, che permette di adattarsi alle forme del corpo e di avere una discrezione ottimale per vari tipi di stomie, e soluzioni per la cura delle stomie SenSura, oltre ad accessori per stomie con il marchio Brava.

Coloplast A/S Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Coloplast con la sua capitalizzazione di mercato?
COLO B statistiche fondamentali
Capitalizzazione di mercato	DKK 202.89b
Guadagni(TTM)	DKK 5.05b
Ricavi(TTM)	DKK 27.03b

39.7x

Rapporto P/E

7.4x

Rapporto P/S

COLO B è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
COLO B Conto economico (TTM)
Ricavi	DKK 27.03b
Costo del fatturato	DKK 8.76b
Profitto lordo	DKK 18.27b
Altre spese	DKK 13.22b
Guadagni	DKK 5.05b

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

Feb 04, 2025

Utile per azione (EPS)	22.44
Margine lordo	67.59%
Margine di profitto netto	18.69%
Rapporto debito/patrimonio netto	120.6%

Come si è comportato COLO B nel lungo periodo?

Vedi performance storica e confronto

Dividendi

2.5%

Rendimento attuale del dividendo

98%

Rapporto di remunerazione

COLO B paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di COLO B

Quando è necessario acquistare COLO B per ricevere un dividendo imminente?
Coloplast date dei dividendi
Data di stacco del dividendo	Dec 06 2024
Data di pagamento dei dividendi	Dec 10 2024
Giorni fino al dividendo Ex	17 days
Giorni prima della data di pagamento dei dividendi	21 days

COLO B paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di COLO B

COLO B Panoramica delle azioni

Premi

Analisi del rischio

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Coloplast A/S Concorrenti

CPSE:DEMANT

DKK 57.6b

CPSE:AMBU B

DKK 31.7b

CPSE:EMBLA

DKK 15.1b

NasdaqGS:COO

US$19.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being